|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CROCC |
Gene summary for CROCC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CROCC | Gene ID | 9696 |
| Gene name | ciliary rootlet coiled-coil, rootletin | |
| Gene Alias | ROLT | |
| Cytomap | 1p36.13 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q5TZA2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9696 | CROCC | P20T-E | Human | Esophagus | ESCC | 4.37e-10 | 1.91e-01 | 0.1124 |
| 9696 | CROCC | P21T-E | Human | Esophagus | ESCC | 5.14e-10 | 1.75e-01 | 0.1617 |
| 9696 | CROCC | P22T-E | Human | Esophagus | ESCC | 1.81e-06 | 1.40e-01 | 0.1236 |
| 9696 | CROCC | P23T-E | Human | Esophagus | ESCC | 2.44e-07 | 1.91e-01 | 0.108 |
| 9696 | CROCC | P26T-E | Human | Esophagus | ESCC | 6.40e-04 | 1.80e-01 | 0.1276 |
| 9696 | CROCC | P27T-E | Human | Esophagus | ESCC | 1.30e-15 | 3.52e-01 | 0.1055 |
| 9696 | CROCC | P28T-E | Human | Esophagus | ESCC | 4.32e-49 | 9.08e-01 | 0.1149 |
| 9696 | CROCC | P30T-E | Human | Esophagus | ESCC | 5.58e-11 | 4.20e-01 | 0.137 |
| 9696 | CROCC | P31T-E | Human | Esophagus | ESCC | 5.85e-03 | 1.49e-01 | 0.1251 |
| 9696 | CROCC | P32T-E | Human | Esophagus | ESCC | 1.40e-12 | 1.36e-01 | 0.1666 |
| 9696 | CROCC | P36T-E | Human | Esophagus | ESCC | 3.10e-06 | 2.63e-01 | 0.1187 |
| 9696 | CROCC | P37T-E | Human | Esophagus | ESCC | 1.87e-12 | 3.27e-01 | 0.1371 |
| 9696 | CROCC | P40T-E | Human | Esophagus | ESCC | 1.35e-04 | 1.63e-01 | 0.109 |
| 9696 | CROCC | P42T-E | Human | Esophagus | ESCC | 8.50e-14 | 4.34e-01 | 0.1175 |
| 9696 | CROCC | P44T-E | Human | Esophagus | ESCC | 8.95e-03 | 9.97e-02 | 0.1096 |
| 9696 | CROCC | P47T-E | Human | Esophagus | ESCC | 2.49e-05 | 1.78e-01 | 0.1067 |
| 9696 | CROCC | P48T-E | Human | Esophagus | ESCC | 5.01e-11 | 3.05e-01 | 0.0959 |
| 9696 | CROCC | P49T-E | Human | Esophagus | ESCC | 1.76e-03 | 4.05e-01 | 0.1768 |
| 9696 | CROCC | P52T-E | Human | Esophagus | ESCC | 8.09e-09 | 2.45e-01 | 0.1555 |
| 9696 | CROCC | P54T-E | Human | Esophagus | ESCC | 1.29e-15 | 3.76e-01 | 0.0975 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
| GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
| GO:00018949 | Cervix | CC | tissue homeostasis | 57/2311 | 268/18723 | 2.43e-05 | 4.21e-04 | 57 |
| GO:00516567 | Cervix | CC | establishment of organelle localization | 76/2311 | 390/18723 | 3.17e-05 | 5.21e-04 | 76 |
| GO:00602498 | Cervix | CC | anatomical structure homeostasis | 63/2311 | 314/18723 | 6.03e-05 | 8.68e-04 | 63 |
| GO:19021153 | Cervix | CC | regulation of organelle assembly | 40/2311 | 186/18723 | 2.92e-04 | 3.15e-03 | 40 |
| GO:19021171 | Cervix | CC | positive regulation of organelle assembly | 19/2311 | 67/18723 | 3.42e-04 | 3.58e-03 | 19 |
| GO:01200328 | Cervix | CC | regulation of plasma membrane bounded cell projection assembly | 38/2311 | 186/18723 | 1.14e-03 | 9.35e-03 | 38 |
| GO:00604917 | Cervix | CC | regulation of cell projection assembly | 38/2311 | 188/18723 | 1.40e-03 | 1.10e-02 | 38 |
| GO:00018957 | Cervix | CC | retina homeostasis | 19/2311 | 79/18723 | 2.94e-03 | 1.94e-02 | 19 |
| GO:19038294 | Colorectum | FAP | positive regulation of cellular protein localization | 79/2622 | 276/18723 | 1.59e-10 | 4.38e-08 | 79 |
| GO:00516563 | Colorectum | FAP | establishment of organelle localization | 97/2622 | 390/18723 | 5.91e-09 | 9.48e-07 | 97 |
| GO:00313463 | Colorectum | FAP | positive regulation of cell projection organization | 82/2622 | 353/18723 | 1.78e-06 | 7.35e-05 | 82 |
| GO:00018944 | Colorectum | FAP | tissue homeostasis | 61/2622 | 268/18723 | 6.71e-05 | 1.28e-03 | 61 |
| GO:00602494 | Colorectum | FAP | anatomical structure homeostasis | 69/2622 | 314/18723 | 7.51e-05 | 1.37e-03 | 69 |
| GO:01200323 | Colorectum | FAP | regulation of plasma membrane bounded cell projection assembly | 39/2622 | 186/18723 | 5.84e-03 | 3.73e-02 | 39 |
| GO:0010669 | Colorectum | FAP | epithelial structure maintenance | 10/2622 | 30/18723 | 5.90e-03 | 3.75e-02 | 10 |
| GO:00604912 | Colorectum | FAP | regulation of cell projection assembly | 39/2622 | 188/18723 | 7.01e-03 | 4.29e-02 | 39 |
| GO:190382926 | Esophagus | HGIN | positive regulation of cellular protein localization | 75/2587 | 276/18723 | 3.19e-09 | 2.30e-07 | 75 |
| GO:005165616 | Esophagus | HGIN | establishment of organelle localization | 90/2587 | 390/18723 | 4.27e-07 | 1.94e-05 | 90 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CROCC | SNV | Missense_Mutation | rs764904297 | c.1060N>A | p.Glu354Lys | p.E354K | Q5TZA2 | protein_coding | tolerated(0.7) | benign(0.09) | TCGA-A2-A4RX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CROCC | SNV | Missense_Mutation | c.3904G>A | p.Glu1302Lys | p.E1302K | Q5TZA2 | protein_coding | deleterious(0.01) | possibly_damaging(0.655) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CROCC | SNV | Missense_Mutation | novel | c.1789N>A | p.Ala597Thr | p.A597T | Q5TZA2 | protein_coding | tolerated(0.35) | benign(0.003) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CROCC | SNV | Missense_Mutation | c.3290G>C | p.Arg1097Pro | p.R1097P | Q5TZA2 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AO-A12H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| CROCC | SNV | Missense_Mutation | rs745666217 | c.2320N>T | p.Arg774Trp | p.R774W | Q5TZA2 | protein_coding | deleterious(0) | possibly_damaging(0.799) | TCGA-AR-A24M-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| CROCC | SNV | Missense_Mutation | c.3290G>C | p.Arg1097Pro | p.R1097P | Q5TZA2 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-B6-A1KC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CROCC | SNV | Missense_Mutation | novel | c.3778N>A | p.Glu1260Lys | p.E1260K | Q5TZA2 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CROCC | SNV | Missense_Mutation | c.2371G>C | p.Glu791Gln | p.E791Q | Q5TZA2 | protein_coding | deleterious(0.02) | benign(0.097) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| CROCC | SNV | Missense_Mutation | c.4649N>A | p.Thr1550Asn | p.T1550N | Q5TZA2 | protein_coding | tolerated(0.72) | benign(0.037) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| CROCC | SNV | Missense_Mutation | c.3290N>C | p.Arg1097Pro | p.R1097P | Q5TZA2 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-BH-A0E9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |